Oct 14, 2022 7:08 am EDT CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
Oct 10, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 28, 2022 4:01 pm EDT Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
Aug 31, 2022 4:01 pm EDT Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference
Aug 08, 2022 4:01 pm EDT Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
Aug 04, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 03, 2022 4:01 pm EDT Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
Aug 01, 2022 4:01 pm EDT Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
Jul 12, 2022 4:30 pm EDT Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
Jul 06, 2022 4:01 pm EDT Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022